Clinical Trial Update: Efficacy and Safety Study of Kedrion IVIG 10% to Treat Subjects With Primary Immunodeficiency (PID) [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating Kedrion IVIG 10% for efficacy and safety in subjects with primary immunodeficiency shows completed status with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Agammaglobulinemia
• Antibody Deficiency
• Hypogammaglobulinemia
• Immunodeficiency

Drugs mentioned

• Kedrion IVIG 10% (intravenous immunoglobulin G)

Snippet

Sponsor: Kedrion S.p.A. | Conditions: Primary Immunodeficiency, Agammaglobulinemia | Phase 3 | Status: COMPLETED | Results posted: 2021-02-16